During the past 12 months, Assertio Holdings's average EBITDA Per Share Growth Rate was -337.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -196.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Assertio Holdings was 95.60% per year. The lowest was -196.80% per year. And the median was -5.80% per year.
Competitive Comparison of Assertio Holdings's 3-Year EBITDA Growth Rate
For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assertio Holdings's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Assertio Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Assertio Holdings 3-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Assertio Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Assertio Holdings (Assertio Holdings) Business Description
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASRT has been successfully added to your